Anixa Biosciences, Inc.
Company Snapshot: Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.anixa.com.
- Feb 25 2021 Anixa Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference
- Feb 16 2021 Anixa Biosciences Begins Animal Testing of Covid-19 Therapeutic Candidates
- Jan 13 2021 Anixa Biosciences to Present at the B. Riley Oncology Investor Conference
- Jan 5 2021 Anixa Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference